Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could spare brain tumor patients from repeated surgeries

NCT ID NCT05133154

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a simple blood test can help diagnose and monitor low-grade gliomas, a type of slow-growing brain tumor. Researchers will collect blood samples from 50 patients undergoing brain surgery to look for circulating tumor cells and other markers. The goal is to find a non-invasive way to track tumor growth and detect changes without repeated biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to help diagnose and monitor low-grade gliomas without repeated surgeries.
What could go wrong
This is an early exploratory study with only 50 participants. It may not find reliable blood markers, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient aged ≥ 18, no age limit * A signed informed consent obtained before any study specific procedures * Patient affiliated to a French social security system * Patient ability to understand experimental procedures * Patient able to speak, read and understand French Also for the "Low-grade glioma" group, the following inclusion criteria applies: \- Brain surgery for a suspected low-grade tumor, histologically confirmed on tumor sample Also for the "High-grade glioma" group, the following inclusion criteria applies: \- Brain surgery for a suspected high-grade glioma, histologically confirmed on tumor sample Also for the "Control group, the following inclusion criteria applies: \- Brain surgery for a non-tumor disease (cavernoma, arteriovenous malformation) Exclusion Criteria: * Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to terminate the study * Pregnant and/or breastfeeding women (this will be checked in declarative way) * Patients with medical history of cancer other than the brain tumor, whatever the treatment received Also, for the "Low-grade glioma" group, the following exclusion criteria applies: * Previous chemotherapy or radiation therapy for the low-grade glioma (but previous surgery/ies is/are allowed) * No indication for chemotherapy for 6 month after surgery Also, for the "High-grade glioma" group, the following exclusion criteria applies: \- Previous chemotherapy or radiation therapy for the glioma Also, for the "control" group, the following exclusion criteria applies: \- Diagnosis or suspicion of primary or secondary brain tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioma low grade glioma malignant glioma Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

  • University Hospital, Montpellier

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.